Celltrion has launched Steqeyma (ustekinumab-stba), its biosimilar of Stelara (ustekinumab), at list price at an 85% discount ...

Celltrion today announced the U.S. launch of STEQEYMA® (ustekinumab-stba), a biosimilar to STELARA® (ustekinumab), following ...

Celltrion and Formycon with Fresenius Kabi launched their respective ustekinumab biosimilars (Steqeyma and Otulfi), joining 4 ...

Two-thirds of patients with moderate or severe plaque psoriasis had complete or nearly complete clearance at 4 months with an ...

The table below is a review of notable updates that occurred in February 2025 for investigational products in development (not an inclusive list ... and Sanofi) Interleukin-4 receptor alpha ...

Until about 20 years ago, systemic treatment options for moderate/severe psoriasis were limited and nonspecific. To get an ...

The stress axis that has been most extensively studied in relation to stress is unquestionably the hypothalamic pituitary ...

Each year Forbes ranks the world based on a variety of categories ranging from the wealthiest people on the planet to the best colleges America has to offer.

Focus on everything you need to get done with a to-do list app filled with smart features. Whether you're using the desktop app at home or the mobile app on the go, access your task list and stay ...

Mammalian genomes are organized by multi-level folding, yet how this organization contributes to cell type-specific transcription remain unclear. We uncovered that the nuclear protein SATB1 ...

Simlandi and adalimumab-adaz have been with on formulary, along with Humira, beginning Jan. 1, 2025, Arpit Patel, Pharm.D., MedImpact vice president, Trade Relations, said in a LinkedIn video.